Alfresa Pharma, AnGes MG Inc. Sign Joint Development Contract For Atopic Dermatitis Drug 
10/19/2005 5:09:29 PM

Tokyo (JCNN) - Alfresa Holdings (TSE: 2784) announced on July 8 that its wholly owned subsidiary Alfresa Pharma has signed a contract with AnGes MG (TSE: 4563) for the development of atopic dermatitis drug using NF-kappa B decoy oligodeoxynucleotide, a type of nucleic acid drug that AnGes MG is developing with the aim of developing applications in atopic dermatitis and rheumatic arthritis.